Literature DB >> 20691388

Medical management of variceal hemorrhage.

Tram B Cat1, Xi Liu-DeRyke.   

Abstract

Gastroesophageal variceal hemorrhage is a major complication of portal hypertension in 50% to 60% of patients with liver cirrhosis and is a frequent cause of mortality in these patients. The prevalence of variceal hemorrhage is approximately 5% to 15% yearly, and early variceal rebleeding has a rate of occurrence of 30% to 40% within the first 6 weeks. More than 50% of patients who survive after the first bleeding episode will experience recurrent bleeding within 1 year. Management of gastroesophageal varices should include prevention of initial and recurrent bleeding episodes and control of active hemorrhage. Therapies used in the management of gastroesophageal variceal hemorrhage may include pharmacologic therapy (vasoactive agents, nonselective b-blockers, and antibiotic prophylaxis), endoscopic therapy, transjugular intrahepatic portosystemic shunt, and shunt surgery. This article focuses primarily on pharmacologic management of acute variceal hemorrhage. (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20691388     DOI: 10.1016/j.ccell.2010.02.004

Source DB:  PubMed          Journal:  Crit Care Nurs Clin North Am        ISSN: 0899-5885            Impact factor:   1.326


  3 in total

1.  CXCL12 induces hepatic stellate cell contraction through a calcium-independent pathway.

Authors:  Yedidya Saiman; Ritu Agarwal; DaShawn A Hickman; Michel Fausther; Ahmed El-Shamy; Jonathan A Dranoff; Scott L Friedman; Meena B Bansal
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-06-27       Impact factor: 4.052

2.  Treatment outcomes of percutaneous transhepatic variceal embolization versus transjugular intrahepatic portosystemic shunt for gastric variceal bleeding.

Authors:  Kai Zhang; Xiaoyan Sun; Guangchuan Wang; Mingyan Zhang; Zhe Wu; Xiangguo Tian; Chunqing Zhang
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

3.  A randomized controlled study of fuzheng huayu capsule for prevention of esophageal variceal bleeding in patients with liver cirrhosis.

Authors:  Jie Gu; Qin Zhang; Dongying Xue; Hong Cai; Lieming Xu
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-21       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.